tetano
Editor, Senior Moderator
J Rheumatol
. 2021 Sep 1;jrheum.210480.
doi: 10.3899/jrheum.210480. Online ahead of print.
COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bonnie L Bermas[SUP] 1 [/SUP], Milena Gianfrancesco[SUP] 1 [/SUP], Helen L Tanner[SUP] 1 [/SUP], Andrea M Seet[SUP] 1 [/SUP], Mathia C Aguiar[SUP] 1 [/SUP], Nasra K Al Adhoubi[SUP] 1 [/SUP], Samar Al Emadi[SUP] 1 [/SUP], Bernardo M Cunha[SUP] 1 [/SUP], Rachael Flood[SUP] 1 [/SUP], Daria A Kusevich[SUP] 1 [/SUP], Eoghan M McCarthy[SUP] 1 [/SUP], Naomi J Patel[SUP] 1 [/SUP], Eric Ruderman[SUP] 1 [/SUP], Sebastian E Sattui[SUP] 1 [/SUP], Savino Sciascia[SUP] 1 [/SUP], Faizah Siddique[SUP] 1 [/SUP], Mario O Valenzuela-Almada[SUP] 1 [/SUP], Leanna M Wise[SUP] 1 [/SUP], Angus B Worthing[SUP] 1 [/SUP], JoAnn Zell[SUP] 1 [/SUP], Suleman Bhana[SUP] 1 [/SUP], Wendy Costello[SUP] 1 [/SUP], Ali Duarte-Garcia[SUP] 1 [/SUP], Rebecca Grainger[SUP] 1 [/SUP], Laure Gossec[SUP] 1 [/SUP], Jonathan S Hausmann[SUP] 1 [/SUP], Kimme Hyrich[SUP] 1 [/SUP], Saskia Lawson-Tovey[SUP] 1 [/SUP], Jean W Liew[SUP] 1 [/SUP], Emily Sirotich[SUP] 1 [/SUP], Jeffrey Sparks[SUP] 1 [/SUP], Paul Sufka[SUP] 1 [/SUP], Zachary Wallace[SUP] 1 [/SUP], Pedro M Machado[SUP] 1 [/SUP], Anja Strangfeld[SUP] 1 [/SUP], Megan E B Clowse[SUP] 1 [/SUP], Jinoos Yazdany[SUP] 1 [/SUP], Philip C Robinson[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To describe coronavirus disease-2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection.
Methods: Since March 2020 the COVID-19 Global Rheumatology Alliance (GRA) has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers.
Results: We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24-45 years. Rheumatic disease diagnoses included: rheumatoid arthritis (n=9), systemic lupus erythematosus (n=9), psoriatic/other inflammatory arthritides (n=8) and anti-phospholipid antibody syndrome (n=6). Most had a term birth (16/22), with 3 pre-term births, one termination, one miscarriage and one woman yet to deliver at time of report. A quarter (n=10/39) of pregnant women were hospitalised following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalised); no patient died. The majority did not receive specific medication treatment for their COVID-19 (n=32/39, 82%), seven patients received some combination of anti-malarials, colchicine, anti-IL-1beta, azithromycin, glucocorticoids, and lopinavir/ritonavir.
Conclusion: Women with rheumatic diseases who were pregnant at the time of COVID-19 had favourable outcomes. These data have limitations due to the small size and methodology, though they provide cautious optimism for pregnancy outcomes for women with rheumatic disease given the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
. 2021 Sep 1;jrheum.210480.
doi: 10.3899/jrheum.210480. Online ahead of print.
COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bonnie L Bermas[SUP] 1 [/SUP], Milena Gianfrancesco[SUP] 1 [/SUP], Helen L Tanner[SUP] 1 [/SUP], Andrea M Seet[SUP] 1 [/SUP], Mathia C Aguiar[SUP] 1 [/SUP], Nasra K Al Adhoubi[SUP] 1 [/SUP], Samar Al Emadi[SUP] 1 [/SUP], Bernardo M Cunha[SUP] 1 [/SUP], Rachael Flood[SUP] 1 [/SUP], Daria A Kusevich[SUP] 1 [/SUP], Eoghan M McCarthy[SUP] 1 [/SUP], Naomi J Patel[SUP] 1 [/SUP], Eric Ruderman[SUP] 1 [/SUP], Sebastian E Sattui[SUP] 1 [/SUP], Savino Sciascia[SUP] 1 [/SUP], Faizah Siddique[SUP] 1 [/SUP], Mario O Valenzuela-Almada[SUP] 1 [/SUP], Leanna M Wise[SUP] 1 [/SUP], Angus B Worthing[SUP] 1 [/SUP], JoAnn Zell[SUP] 1 [/SUP], Suleman Bhana[SUP] 1 [/SUP], Wendy Costello[SUP] 1 [/SUP], Ali Duarte-Garcia[SUP] 1 [/SUP], Rebecca Grainger[SUP] 1 [/SUP], Laure Gossec[SUP] 1 [/SUP], Jonathan S Hausmann[SUP] 1 [/SUP], Kimme Hyrich[SUP] 1 [/SUP], Saskia Lawson-Tovey[SUP] 1 [/SUP], Jean W Liew[SUP] 1 [/SUP], Emily Sirotich[SUP] 1 [/SUP], Jeffrey Sparks[SUP] 1 [/SUP], Paul Sufka[SUP] 1 [/SUP], Zachary Wallace[SUP] 1 [/SUP], Pedro M Machado[SUP] 1 [/SUP], Anja Strangfeld[SUP] 1 [/SUP], Megan E B Clowse[SUP] 1 [/SUP], Jinoos Yazdany[SUP] 1 [/SUP], Philip C Robinson[SUP] 1 [/SUP]
Affiliations
- PMID: 34470798
- DOI: 10.3899/jrheum.210480
Abstract
Objective: To describe coronavirus disease-2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection.
Methods: Since March 2020 the COVID-19 Global Rheumatology Alliance (GRA) has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers.
Results: We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24-45 years. Rheumatic disease diagnoses included: rheumatoid arthritis (n=9), systemic lupus erythematosus (n=9), psoriatic/other inflammatory arthritides (n=8) and anti-phospholipid antibody syndrome (n=6). Most had a term birth (16/22), with 3 pre-term births, one termination, one miscarriage and one woman yet to deliver at time of report. A quarter (n=10/39) of pregnant women were hospitalised following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalised); no patient died. The majority did not receive specific medication treatment for their COVID-19 (n=32/39, 82%), seven patients received some combination of anti-malarials, colchicine, anti-IL-1beta, azithromycin, glucocorticoids, and lopinavir/ritonavir.
Conclusion: Women with rheumatic diseases who were pregnant at the time of COVID-19 had favourable outcomes. These data have limitations due to the small size and methodology, though they provide cautious optimism for pregnancy outcomes for women with rheumatic disease given the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.